Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Other OTC  >  US Nuclear Corp.    UCLE

US NUCLEAR CORP.

(UCLE)
  Report
SummaryQuotesChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

US Nuclear : Secures Its Position at Bioelectronics Startup Grapheton

10/19/2020 | 08:31am EST

LOS ANGELES, CA, Oct. 19, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire – In addition to US Nuclear’s (OTC: UCLE) 40% stake in Grapheton, CEO Robert Goldstein has recently taken a seat on Grapheton’s board of directors and will now serve as Chief Strategy Officer. As Chief Strategy Officer for Grapheton, Robert Goldstein will help the business become a leader in the new field of bioelectronics and will cement the partnership between US Nuclear and Grapheton.     

Grapheton’s unique, patented bioelectronic implants lead the world in bio-compatibility and longevity. Bioelectronics are becoming popular among researchers and doctors, and the bioelectronics market is likely to experience tremendous growth in the near future.  In recent years, there have been numerous breakthroughs using bioelectronics technology. A notable example, bioelectronic devices have been researched and used in clinical trials to treat rheumatoid arthritis and Crohn’s disease by electrically stimulating the vagus nerve to control inflammation and the immune response.   

Bioelectronics has the potential to become a vital branch of medical treatment. Medical care, in general, has made many advances in recent years, but there are a great many diseases, conditions, injuries, and remaining unmet patient needs that still need to be urgently addressed.

Bioelectronics have several key advantages over traditional treatment methods. The primary advantage is that bioelectronics can be used to treat conditions that current drugs or procedures are unable to treat (i.e., spinal-cord injuries, addiction, depression, Parkinson’s, stroke, multiple sclerosis, regaining vision, and more). A second major advantage is the ability to deliver precise treatment.  For example, a bioelectronic device is used to treat paralysis from a stroke or brain injury by specifically bridging the damaged site and restoring motor transmission, whereas the pharmaceutical approach of prescribing drugs is diffuse, lacking the necessary precision targeting to be effective. Additionally, almost all drugs have the potential for undesired side effects which can build up to severe problems over the course of treatment. Many drugs are given for continuous use of pills or injections, over months or years, whereas bioelectronic interventions are designed to repair a problem permanently while allowing for periodic non-invasive adjustments made by the user, doctor, or automatically. Bioelectronic devices can also provide precise, localized regulation of misbehaving glands and organs.

Biomedicine is translating new discoveries in science and biological systems into needed medical care and treatment. It utilizes under-recognized electrical and neuro systems and pathways that take advantage of the body’s innate functions.

Robert Goldstein, CEO of US Nuclear, will bring decades of manufacturing, marketing, and leadership experience to help to accelerate Grapheton’s growth into a world leader in bioelectronics technology. 

Safe Harbor Act

This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.

Investors may find additional information regarding US Nuclear Corp. at the SEC website at http://www.sec.gov, or the company’s website at www.usnuclearcorp.com

CONTACT:

US Nuclear Corp. (OTC: UCLE)
Robert I. Goldstein, President, CEO, and Chairman 
Rachel Boulds, Chief Financial Officer
(818) 883 7043
Email: info@usnuclearcorp.com


83970_USNuclearCorpLogo.jpg

Source: US Nuclear Corp.

2020 GlobeNewswire, Inc., source Press Releases

All news about US NUCLEAR CORP.
03/02Think About Taking Your First US Nuclear Fusion Powered Trip to Mars and Back
GL
02/08Grapheton Inc. is Featured on The Stock Day Podcast to Discuss Advanced Neuro..
NE
01/21US Nuclear Corp. Discusses Potential of 2021 Projects with The Stock Day Podc..
NE
01/06US NUCLEAR CORP.  : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
01/06US NUCLEAR  : 2019 Convertible Debenture Now Fully Converted, Closed, and Flat
AQ
2020US Nuclear Corp. Discusses The Progress of Its MIFTEC Contract and Overhuff T..
NE
2020US Nuclear Corp. Announces Third Quarter 2020 Results
GL
2020US NUCLEAR  : Management's Discussion and Analysis of Financial Condition and Re..
AQ
2020US NUCLEAR  : and Grapheton Brain Implants to Help Immobilized Patients
AQ
2020US Nuclear and Grapheton Brain Implants to Help Immobilized Patients
GL
More news
Financials (USD)
Sales 2019 3,54 M - -
Net income 2019 -3,16 M - -
Net cash 2019 0,10 M - -
P/E ratio 2019 -4,28x
Yield 2019 -
Capitalization 15,4 M 15,4 M -
EV / Sales 2018 2,02x
EV / Sales 2019 3,85x
Nbr of Employees 20
Free-Float 48,4%
Chart US NUCLEAR CORP.
Duration : Period :
US Nuclear Corp. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
NameTitle
Robert I. Goldstein Chairman, President & Chief Executive Officer
Rachel Boulds Chief Financial Officer & Secretary
Richard Landry COO & Director-Investor Relations
Michael G. Hastings Director
Dell Williamson Director
Sector and Competitors